I am a Clinician Scientist working in the field of hereditary retinal and macular degenerations. I direct a regional referral service for these diseases at the Ross Eye Institute. My NIH- and VA-funded laboratory is focused on the development of gene-based therapeutics for hereditary retinal degenerations and common age-related macular degeneration.
Education and Training:
Fellowship, Retinal Degenerative Diseases, University of Michigan, Ann Arbor, MI, Clinical/Research Fellowship of Retinitis Pigmentosa Foundation (now Foundation Fighting Blindness) (1994)
Residency, Ophthalmology, Washington Univ. School Medicine, St. Louis MO (1992)
MD, Medicine/Biophysics, Mount Sinai School Medicine, NY (1987)
BA, Microbiology, Rutgers University, New Brunswick, NJ (1979)
Associate Professor with tenure, Ophthalmology, University at Buffalo- State University of New York (2011-present)
Staff Physician, Ophthalmology, VA Western NY Healthcare System (2004-present)
Associate Professor- tenure track, Ophthalmology, University at Buffalo- State University of New York (2004–2011)
Assistant Professor, Ophthalmology, Upstate Medical University- State University of New York (1994–2004)
Lecturer in Ophthalmology, Ophthalmology, University of Michigan (1992–1994)
Fellow in Neurobiology; Staff Physician, Ophthalmology, Washington University School of Medicine; John Cochran Veterans Administration Hospital (1991–1992)
Resident in Ophthalmology (PGY2- PGY4), Ophthalmology, Washington University School of Medicine (1988–1991)
Intern (PGY1), Medicine, St. John's Mercy Medical Center (1987–1988)
Grants and Sponsored Research:
September 2003–September 2007 A Ribozyme Rescue Strategy for Autosomal Dominant Retinitis Pigmentosa National Eye Institute Role: Co-Investigator $975,000
June 1996–May 2001 The Early Receptor Current of Rhodopsin Activation National Eye Institute Role: Co-Investigator $350,000
Brueggemann LI, Sullivan JM. HEK293S cells have functional retinoid processing machinery.. J Gen Physiol. 2002; 119(6).
Sullivan JM, Pietras KM, Shin BJ, Misasi JN. Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa.. Mol Vis. 2002; 8.
Anumonwo J. Voltage and proton sensitivity of rhodopsin activation. Biophys. J.. 2001; 80(19a).
SULLIVAN J. Rhodopsin charge motions in the Schiff base counterion mutant E113Q. Invest. Ophthal. Vis. Sci. 2001; 42(S184).
P Shukla. An electrical approach to study rhodopsin activation in single cells with the early receptor current assay. Methods in Enzymology. 2000; 315.
GM Seigel. Rhodopsin-induced apoptosis in a human cell culture system. Invest. Ophthal. Vis. Sci. 2000; 41(S404).
Shukla P, Sullivan JM. Normal and mutant rhodopsin activation measured with the early receptor current in a unicellular expression system.. J Gen Physiol. 1999; 114(5).
Sullivan JM, Shukla P. Time-resolved rhodopsin activation currents in a unicellular expression system.. Biophys J. 1999; 77(3).
P Shukla. Time-resolved rhodopsin activation: early receptor current studies in a unicellular expression system.. Biophys. J. 1999; 76(148a).
Shukla P. Normal and mutant rhodopsin activation measured with the early receptor current in a unicellular expression system.. J. General Physiology. 1999; 114.
Shukla P. Time-resolved rhodopsin activation currents in a unicellular expression system. Biophysical J. 1999; 77(3).
SULLIVAN J. . Low-cost monochromatic microsecond flash microbeam apparatus for single-cell photolysis of rhodopsin or other photolabile pigments.. Rev. Sci. Inst. 1998.
Satchwell MF. Development of stable cell lines expressing mutant human rhodopsins. Invest. Ophthal. Vis. Sci. 1998; 39(S958).
Shin B. Design and testing of hammerhead ribozymes to cleave full-length opsin mRNA. Invest. Ophthal. Vis. Sci.. 1998; 39(S722).
J Olik. A sutureless self-retaining infusion cannula for pars plana vitrectomy. Amer. J. Ophthalmol. 1990; 110.
Liebovitch LS. Fractal analysis of a voltage dependent potassium channel from cultured mouse hippocampal neurons. Biophysical J. 1987; 52.